Onyx Therapeutics, Inc. 4
4 · Kezar Life Sciences, Inc. · Filed Jun 25, 2018
Insider Transaction Report
Form 4
Onyx Therapeutics, Inc.
10% Owner
Transactions
- Conversion
Series A Redeemable Convertible Preferred Stock
2018-06-25−1,121,384→ 0 total→ Common Stock (1,121,384 underlying) - Conversion
Common Stock
2018-06-25+1,121,384→ 1,121,384 total
Footnotes (3)
- [F1]As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock.
- [F2]These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx.
- [F3]Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock.